Independent peptide education · Evidence annotated · Research use information
Peptide Library / Exenatide

Exenatide Research Guide

Exendin-4-based GLP-1 receptor agonist

FDA-approved drug evidence
ClassificationSingle Peptide
Evidence tierFDA-approved drug evidence
Research statusEducational reference
01 · At a glance

Overview

Exenatide is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.

Dosing & reconstitution guide

Exenatide suggested dosing guide

A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.

FDA-labeled
Suggested starting range5 mcg
Typical reference range5–10 mcg twice daily; extended release 2 mg weekly
FrequencyFormulation dependent
TimingTwice-daily form within 60 minutes before meals
Typical durationLong-term while clinically appropriate
RouteSubcutaneous injection

Titration and protocol notes

Immediate-release and extended-release products are not interchangeable dose-for-dose.

Annotated dosage protocol

Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.

PhaseDoseScheduleWhat this dosage means
Starting phase5 mcgFormulation dependentThe entry dose or lowest studied range, used before any protocol-directed increase.
Treatment range5–10 mcg twice daily; extended release 2 mg weeklyTwice-daily form within 60 minutes before mealsThe range used after initiation. The applicable dose depends on the labeled indication or study design.
Duration / reassessmentLong-term while clinically appropriateReassess before continuingImmediate-release and extended-release products are not interchangeable dose-for-dose. Dose changes should never be inferred from vial size or convenient syringe units.

Exenatide reconstitution example

This worked example uses a 10 mg vial, 2 mL of diluent, and a 5 mcg reference amount.

Vial strength10 mg
Diluent added2 mL
Concentration5 mg/mL
Example draw0.001 mL / 0.1 units
How this example is calculated: 10 mg ÷ 2 mL = 5 mg/mL. The 5 mcg reference amount equals 0.005 mg. That produces a 0.001 mL draw, or 0.1 units on a U-100 syringe.

Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.

Safety, handling, and storage
  • Suggested ranges are educational summaries, not individualized prescriptions.
  • FDA-labeled regimens apply only to the approved product, indication, and delivery system.
  • For experimental compounds, human safety, purity, and effective dosing may be unknown.
  • Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Live concentration math

Exenatide calculator

Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.

Runs in your browser
Concentration5 mg/mL
Draw volume0.001 mL
On the syringe0.1 units
Portions per vial2,000

Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.

02 · How it is studied

Mechanism and research rationale

A peptide derived from exendin-4 that activates the GLP-1 receptor and resists rapid degradation by DPP-4.

Type 2 diabetes

Incretin biology

Glucose regulation

03 · Interpretation

Key facts

  • Evidence tier: FDA-approved drug evidence.
  • Research status and regulatory status are not interchangeable.
  • This page is an educational reference and does not provide personal medical instructions.
04 · Editorial annotations

What to keep in mind

Editorial note: distinguish peer-reviewed findings from supplier or community claims.
Evidence note: study design, species, route and formulation can materially change interpretation.
05 · Sources

References and evidence indexes

  1. PubMed search: Exenatide
  2. ClinicalTrials.gov search
Research notice: This guide is educational and not medical advice. It does not diagnose, treat, prescribe, or recommend personal use.
Exenatide Research Guide | Get Peptide Answers | Get Peptide Answers